ClinicalTrials.gg
Status unknownNCT02726477Updated May 9, 2016

Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema

An interventional study of Wuling San and placebo in Breast Cancer and Lymphedema, sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Status unknown at 3 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-05-09.

Sponsored by Fourth Affiliated Hospital of Guangxi Medical University · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
558th of 1,525
200 · median 120
Started
2016
with 62 others
No phase
328 of 1,936
171 open now
Registered
287th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 558th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 63 that started in 2016, is one of 328 with no phase, and was the 287th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of Wuling San, a traditional Chinese medicine, in reducing arm volume excess in women with stage I-II breast cancer related unilateral lymphedema.

Read the detailed description

The investigators will aim to enroll 200 female adult patients (aged between 20 and 40 years) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for breast cancer related unilateral lymphedema. The investigators will be using a standardized data collection form in this study, where standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent.

03

Conditions studied

  • Breast Cancer
  • Lymphedema
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women completed all primary and treatments (surgery, chemotherapy, radiotherapy)
  • age 20-40 with unilateral BCRL, stage I or II, of 18-25
  • Volume difference ≥300 mL between the normal and lymphedematous upper extremity based on perometry evaluation
  • No evidence of breast cancer recurrence
  • At least 6 months postoperative from axillary lymph node dissection

Exclusion criteria

Exclusion Criteria:

  • Bilateral lymphedema or stage III lymphedema
  • History of bilateral axillary lymph node dissection
  • Recent history of cellulitis in the affected extremity (within last 3 months)
  • Recurrent breast cancer or other
  • Current (within last month) use of chemotherapy for breast or other malignancy
  • Current (within last 3 months) use of radiation for breast or other malignancy
  • Recent (within last month) or current intensive MLD and/or short stretch bandage use
  • Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months)
  • Pregnant or nursing (lactating) women
  • Patients that take drugs like diosmin at the time of enrollment, or within 30 days.
  • Use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
  • Unable to comply with the protocol, measurement and follow-up schedule.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Wuling San

    This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements. A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.

    Drug: Wuling San

  • Placebo comparator
    placebo

    A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.

    Drug: placebo

Interventions

  • DrugWuling San

    Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.

  • Drugplacebo

    Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.

06

What researchers measure

Primary outcomes

  1. volume changes % measured by perometry

    Volume changes in the arm after the therapy will be calculated using the methods established by Anderson et al (2000). Briefly, the difference in volume measurements between the normal and lymphedematous arms at baseline will be compared to the volume differential after drug treatment (i.e volume excess) using the following formula: Change in absolute edema=(Vo-Vc)B-(Vo-Vc)3 months/(Vo-Vc)B Change in ln ratio=ln (Vo/Vc)B-ln (Vo/Vc)3 months. Vo is the volume of the lymphedema arm. Vc is the volume of the contralateral arm. Andersen, L., Højris, I., Erlandsen, M., \& Andersen, J. (2000). Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage: a randomized study\[J\]. Acta Oncologica, 2000, 39(3): 399-405.

    Time frame: baseline and 2 months

Secondary outcomes

  1. adverse events

    number of participants with serious and non-serious adverse events

    Time frame: baseline and 2 months

07

Study locations

3 of 3 sites recruiting
  • Liuzhou Hospital of Traditional Chinese Medicine
    Liuzhou, Guangxi 545000, China
    Recruiting
  • Liuzhou Maternity and Child Healthcare Hospital
    Liuzhou, Guangxi 545000, China
    Recruiting
  • The Fourth Affiliated Hospital of Guangxi Medical University
    Liuzhou, Guangxi 545000, China
    Recruiting
08

References and documents

Publications

  • Andersen L, Hojris I, Erlandsen M, Andersen J. Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage--a randomized study. Acta Oncol. 2000;39(3):399-405. doi: 10.1080/028418600750013186. PubMed 10987238 ↗
  • Zhu H, Peng Z, Dai M, Zou Y, Qin F, Chen J, Song L, He B, Lv X, Dai S. Efficacy and safety of Wuling San for treatment of breast-cancer-related upper extremity lymphoedema: study protocol for a pilot trial. BMJ Open. 2016 Dec 16;6(12):e012515. doi: 10.1136/bmjopen-2016-012515. PubMed 27986736 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Sep 2017 and a completion of May 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2016
First posted
Apr 1, 2016
Start
Apr 2016
Primary completionEst.
Sep 2017
CompletionEst.
May 2018
Last update
May 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02726477
Lead sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Collaborators
Liuzhou Maternity and Child Healthcare Hospital, Liuzhou Hospital of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Apr 2016
Primary completion
Sep 2017 (estimated)
Completion
May 2018 (estimated)
Last update
May 9, 2016

Study contacts

Zheng Peng
Contact
labstar@qq.com
+86 07723815334
Xiangcheng Wei
Contact
Xiangcheng Wei
principal investigator · Guangxi Medical University Institutional Review Board

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion